Pulmonary vascular disease & thromboembolism

Safety of treating acute pulmonary embolism at home: an individual patient data meta-analysis

Eur Heart JPublished Individual patient data meta-analysis of prospective cohort studies and RCTs

Authors' conclusion

The incidence of adverse events in home-treated PE patients, selected by a validated triage tool, was very low.

Study context

Population
Acute pulmonary embolism (PE) patients treated at home (discharged within 24 h), selected by a predefined triage tool
Participants
2,694 patients10 studies
Outcome
All-cause mortality and adverse events (recurrent VTE, major bleeding and/or all-cause mortality)
Follow-up
14 and 30 days
Methodological detailssystematic search, random effects model
  • Systematic search
  • Random effects model

Pooled result

As reported in the abstract

14-day mortality

0.11%

95% CI 0.0–0.24, I2 = 0

30-day mortality

0.30%

95% CI 0.09–0.51, I2 = 0

14-day adverse events

0.56%

95% CI 0.28–0.84, I2 = 0

30-day adverse events

1.2%

95% CI 0.79–1.6, I2 = 0

Further pooled results

30-day mortality, by cancer (subgroup)

RR (95% CI)
CancerPrediction interval; I2 = 04.9 (2.7–9.1)

14-day adverse events, by subgroup

RR (95% CI)
Pre-existing cardiopulmonary diseasePrediction interval; I2 = 03.5 (1.5–7.9)
Abnormal troponinPrediction interval; I2 = 02.5 (1.3–4.9)
Abnormal (NT-pro)BNPPrediction interval; I2 = 03.9 (1.6–9.8)

30-day adverse events, by subgroup

RR (95% CI)
CancerPrediction interval; I2 = 02.7 (1.4–5.2)
Abnormal troponinPrediction interval; I2 = 02.9 (1.5–5.7)
Abnormal (NT-pro)BNPPrediction interval; I2 = 03.3 (1.6–7.1)

14-day adverse events, by subgroup

Not associated with increased mortality

Original publication

Safety of treating acute pulmonary embolism at home: an individual patient data meta-analysis. Eur Heart J. Published 12 July 2024. doi:10.1093/eurheartj/ehae378

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.